What approach is suggested for extended adjuvant endocrine therapy in a HR+ breast cancer?

This can be a complicated decision for which you need to take into consideration the patient's estimated risk of late recurrence, her understanding of that risk, how well (or poorly) she has tolerated the first 5 years of adjuvant endocrine therapy, and her age and comorbidities, including the prese...

The goal of extended adjuvant endocrine therapy, which is treatment beyond the initial five years, is to reduce the risk of a late cancer recurrence. The decision is highly personalized and based on balancing this potential benefit against side effects and a patient's quality of life.

The most impor...

Just a few additional comments:

First, for premenopausal women who have completed 5 years of tamoxifen, if the risk of recurrence is sufficiently high to justify extended adjuvant therapy, ovarian function suppression and AI should be considered in place of an additional 5 years of tamoxifen. Second...